Read by QxMD icon Read


Lisa Gross, Dirk Sibbing, Christian Schulz, Florian Gärtner, Joachim Pircher, Steffen Massberg, Tobias Petzold
A core research area in the Department of Cardiology at Ludwig-Maximilians-University (LMU) Munich focuses on antiplatelet therapy, its translational aspects, and its underlying mechanism with respect to platelet physiology. We are conducting a broad range of investigator-initiated clinical trials (phase II-IV) and preclinical studies on the topic of antithrombotic therapy for percutaneous coronary intervention patients, platelet activation, and reactivity as well as on novel inhibitors of platelet adhesion...
July 11, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
Donal J Sexton, Declan G de Freitas, Mark A Little, Tomas McHugh, Colm Magee, Peter J Conlon, Conall M O'Seaghdha
We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolism in NS. We report our systematic review of the existing literature on direct-acting oral anticoagulant (DOAC) use in NS, and discuss theoretical issues relevant to their therapeutic use in this clinical scenario...
July 2018: KI Reports
Kathrin I Foerster, Andrea Huppertz, Andreas D Meid, Oliver J Müller, Timolaos Rizos, Lisa Tilemann, Walter E Haefeli, Jürgen Burhenne
Plasma concentrations of direct oral anticoagulants (DOAC) vary largely between individuals, while they correlate well with desired and adverse outcomes. Although regular concentration monitoring of DOAC is not recommended, information on DOAC exposure could be useful in situations, when multiple DOAC clearance pathways are impaired or non-adherence is suspected. Self-sampling techniques, like dried blood spots (DBS), would be particularly useful because they enable collecting information in ambulatory patients at relevant points in time of the dosing interval (e...
July 9, 2018: Analytical Chemistry
Agnieszka Janion-Sadowska, Elżbieta Papuga-Szela, Robert Łukaszuk, Magdalena Chrapek, Anetta Undas
AIMS: Thrombocytopenia was one of the exclusion criteria in randomized trials in which non-vitamin K antagonist oral anticoagulants (NOACs) were tested. The safety of NOACs in patients with atrial fibrillation (AF) and thrombocytopenia remains unclear. METHODS: We studied 62 AF patients aged from 53 to 85 (mean 70.5) years with platelet count from 50 to 100×109/L who were treated with rivaroxaban 15 mg once daily (33.9%), dabigatran 110 mg bid (54.8%) or apixaban 2...
June 27, 2018: Journal of Cardiovascular Pharmacology
Menno V Huisman, Frederikus A Klok
Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and patients remain at increased VTE risk for up to 3 months post-discharge. Recent clinical trials of extended-duration thromboprophylaxis with enoxaparin, rivaroxaban, and apixaban in acute medically ill patients did not demonstrate a net clinical benefit compared with in-hospital thromboprophylaxis, and were shown to be associated with higher risks of major bleeding...
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
Dimitrios Farmakis, Periklis Davlouros, Gregory Giamouzis, George Giannakoulas, Athanasios Pipilis, Georgios Tsivgoulis, John Parissis
Direct or new oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have recently revolutionized the field of antithrombotic therapy for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (NVAF). Randomized controlled trials have shown that these agents have at least comparable efficacy with vitamin K antagonists along with superior safety, at least in what concerns intracranial hemorrhage...
July 5, 2018: Cardiology
P Priyanka, J T Kupec, M Krafft, N A Shah, G J Reynolds
Background: Newer oral anticoagulants (NOACs) are being utilized increasingly for the treatment of venous thromboembolism (VTE). NOAC use is the standard of care for stroke prophylaxis in nonvalvular atrial fibrillation and treatment of acute VTE involving extremities and pulmonary embolism. In contrast, most guidelines in the literature support the treatment of acute portal vein thrombosis (PVT) with low molecular weight heparin (LMWH) and vitamin K antagonists (VKA). Literature evaluating NOAC use in the treatment of acute portal vein thrombosis is sparse...
2018: International Journal of Hepatology
Yana Vinogradova, Carol Coupland, Trevor Hill, Julia Hippisley-Cox
OBJECTIVE: To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin. DESIGN: Prospective open cohort study. SETTING: UK general practices contributing to QResearch or Clinical Practice Research Datalink. PARTICIPANTS: 132 231 warfarin, 7744 dabigatran, 37 863 rivaroxaban, and 18 223 apixaban users without anticoagulant prescriptions for 12 months before study entry, subgrouped into 103 270 patients with atrial fibrillation and 92 791 without atrial fibrillation between 2011 and 2016...
July 4, 2018: BMJ: British Medical Journal
Babar Bashir, Douglas F Stickle, Inna Chervoneva, Walter K Kraft
Apixaban is metabolized by cytochrome P450 (CYP) 3A4 in the liver and intestine, undergoes direct intestinal excretion, and is a substrate to permeability glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. We examined the drug interactions between cyclosporine and tacrolimus (combined inhibitors of CYP3A4, P-gp and, BCRP) with apixaban in 12 healthy adult male volunteers. Apixaban 10 mg was administered orally alone, in combination with 100 mg cyclosporine or 5 mg tacrolimus. Co-administration with cyclosporine resulted in increase in apixaban maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve from time zero to the last quantifiable concentration [AUC(0-tlast) ] with associated geometric mean ratios (GMR) and 90% confidence intervals (CI) of 143% (112, 183) and 120% (97, 148)...
July 3, 2018: Clinical and Translational Science
Graeme Wertheimer, Luke R Bereznicki
BACKGROUND: Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective. OBJECTIVE: To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wales, Australia. METHODS: This retrospective observational study reviewed patients admitted to St John of God Hawkesbury Hospital with AF between June 2016 and June 2017...
January 1, 2018: Journal of Cardiovascular Pharmacology and Therapeutics
Vincent Willey, Jessica Franchino-Elder, An-Chen Fu, Cheng Wang, Stephen Sander, Hiangkiat Tan, Elizabeth Kraft, Rahul Jain
OBJECTIVES: With the approval of new non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation (NVAF), it is anticipated that their introduction may change NVAF treatment patterns; however, there is limited supporting real-world evidence. This study investigated guideline-recommended oral anticoagulation (OAC) treatment and persistence in newly diagnosed patients with NVAF to understand demographic and clinical characteristics. DESIGN: Retrospective observational administrative claims study in the USA...
June 30, 2018: BMJ Open
Elodie Boissier, Steve Genebrier, Karim Lakhal, Fabienne Nedelec-Gac, Marc Trossaërt, Catherine Ternisien, Isabelle Gouin-Thibault
No abstract text is available yet for this article.
June 30, 2018: Thrombosis and Haemostasis
Alejandro R Trevino, Luis Perez, Carlos Jerjes-Sanchez, David Rodriguez, Jathniel Panneflek, Claudia Ortiz-Ledesma, Francisco Nevarez, Vicente Jimenez, Felipe Valdes, Eduardo de Obeso
We report the case of a 61-year-old man who presented at the Emergency Department (ED), complaining of sudden-onset dyspnea and chest pain after a long flight from Tokyo to Houston. Considering his clinical stability and sPESI 0, enoxaparin 1 mg/kg BID was started for 24 h, and the patient was then considered for early discharge with apixaban 10 mg BID. Direct-factor Xa inhibition did not improve extensive thrombus burden and right ventricular dysfunction despite D-dimer measurement reduction. Because of the treatment failure, we considered thrombolysis...
June 22, 2018: American Journal of Emergency Medicine
Munir Pirmohamed
Oral anticoagulants are required for both treatment and prophylaxis in many different diseases. Clinicians and patients now have a choice of oral anticoagulants, including the vitamin K antagonists (of which warfarin is the most widely used and is used as the exemplar in this paper), and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban, and edoxaban). This paper explores the recent advances and controversies in oral anticoagulation. While some commentators may favour a complete switchover to DOACs, this paper argues that warfarin still has a place in therapy, and a stratified approach that enables the correct choice of both drug and dose would improve both patient outcomes and affordability...
June 28, 2018: Journal of Personalized Medicine
Christina Ji-Young Lee, Thomas Alexander Gerds, Nicholas Carlson, Anders Nissen Bonde, Gunnar Hilmar Gislason, Morten Lamberts, Jonas Bjerring Olesen, Jannik Langtved Pallisgaard, Morten Lock Hansen, Christian Torp-Pedersen
BACKGROUND: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC) and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI). OBJECTIVES: This study aimed to investigate the risk of MI associated with the use of apixaban, dabigatran, rivaroxaban, and VKA in patients with atrial fibrillation. METHODS: Patients with atrial fibrillation were identified using Danish health care registers and stratified by initial oral anticoagulant treatment...
July 3, 2018: Journal of the American College of Cardiology
Konstantinos C Siontis, Xiaosong Zhang, Ashley Eckard, Nicole Bhave, Doug E Schaubel, Kevin He, Anca Tilea, Austin G Stack, Rajesh Balkrishnan, Xiaoxi Yao, Peter A Noseworthy, Nilay D Shah, Rajiv Saran, Brahmajee K Nallamothu
Background -Patients with end-stage kidney disease (ESKD) on dialysis were excluded from clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised concern regarding the safety of dabigatran and rivaroxaban, but apixaban has not been evaluated despite current labeling supporting its use in this population. The goal of this study was to determine patterns of apixaban use and its associated outcomes in dialysis-dependent ESKD patients with AF. Methods -We performed a retrospective cohort study of Medicare beneficiaries included in the United States Renal Data System (October 2010 to December 2015)...
June 28, 2018: Circulation
Michael McGee, Emily Shiel, Stephen Brienesse, Stuart Murch, Robert Pickles, James Leitch
Staphylococcus aureus myocarditis is a rare diagnosis with a high mortality rate, usually seen in people who are immunocompromised. Here, we report a case of a 44-year-old man on methotrexate for rheumatoid arthritis who presented in septic shock and was diagnosed with staphylococcus aureus myocarditis. The myocarditis was associated with a left ventricular apical thrombus, with normal systolic function. The myocarditis and associated thrombus were characterised on transthoracic echocardiogram and subsequently on cardiac magnetic resonance imaging...
2018: Case Reports in Cardiology
Conor McQuillan, Alastair Gray, Aileen Kearney, Ian B A Menown
INTRODUCTION: Numerous important cardiology clinical trials have been published or presented at major international meetings during 2017. This paper aims to summarize these trials and place them in clinical context. METHODS: The authors reviewed clinical trials presented at major cardiology conferences during 2017 including the American College of Cardiology, European Association for Percutaneous Cardiovascular Interventions, European Society of Cardiology, European Association for the Study of Diabetes, Transcatheter Cardiovascular Therapeutics, and the American Heart Association...
June 14, 2018: Advances in Therapy
Guowei Li, Gregory Y H Lip, Anne Holbrook, Yaping Chang, Torben B Larsen, Xin Sun, Jie Tang, Lawrence Mbuagbaw, Daniel M Witt, Mark Crowther, Lehana Thabane, Mitchell A H Levine
The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Direct comparisons between NOACs in trials are lacking, leaving an important clinical decision-making gap. We aimed to perform a systematic review and meta-analysis to summarize the evidence of observational studies for direct comparative effectiveness and safety amongst NOACs in patients with AF. Conference proceedings and electronic databases including MEDLINE, CINAHL, EMBASE and PUBMED were systematically searched...
June 8, 2018: European Journal of Epidemiology
Caroline Sindet-Pedersen, Laila Staerk, Jannik Langtved Pallisgaard, Thomas Alexander Gerds, Jeffrey S Berger, Christian Torp-Pedersen, Gunnar H Gislason, Jonas Bjerring Olesen
Aim: To investigate the risk of all-cause mortality, recurrent VTE, and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban. Methods and results: Using Danish nationwide registries, patients with VTE treated with rivaroxaban or apixaban in the period from January 1st 2015 to June 30th 2017 were identified. Standardized absolute risks were estimated based on outcome-specific Cox regression models, adjusted for potential confounders...
June 26, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"